Abstract
Purpose
The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve current treatment regimens.
Methods
The baseline and post-treatment SLD of target lesion was recorded and the maximum percent change of the SLD from baseline was designated as SLD-change score. The optimal cut-off value was obtained using the X-tile program. The relationship between SLD-change score and survival outcome (PFS, OS) was evaluated.
Results
10% cut-off value of SLD-change score was found to be most distinctive for PFS. Responders defined according to this cut-off value showed a significant improvement for PFS and OS. Bone metastasis and brain metastasis were also two independent prognostic factors of PFS and OS, respectively.
Conclusions
10% SLD change score could discriminate for ICIs treatment response, which holds great promise in promoting the development of precise immunotherapeutic strategy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639
Brahmer J et al (2019) O.02 long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): impact of early disease control and response. J Thorac Oncol 14(11):S1152–S1153
Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259. https://doi.org/10.1158/1078-0432.CCR-04-0713
Cascone T, William WN Jr, Weissferdt A et al (2021) Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504–514. https://doi.org/10.1038/s41591-020-01224-2
Doherty MK, Jao K, Shepherd FA, Hazrati L-N, Leighl NB (2015) Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor. J Thorac Oncol off Publ Int Assoc Study Lung Cancer 10:e100–e101. https://doi.org/10.1097/JTO.0000000000000587
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133–150
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550
Hochmair MJ, Schwab S, Burghuber OC, Krenbek D, Prosch H (2017) Symptomati pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer Amst Neth 113:4–6. https://doi.org/10.1016/j.lungcan.2017.08.020
Hopkins AM et al (2020) Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab. J Immunother Cancer 8(1):e000500. https://doi.org/10.1136/jitc-2019-000500
Jimenez-Sanchez A et al (2017) Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170:927–938
Kim SI et al (2021) Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front Immunol 11:629722. https://doi.org/10.3389/fimmu.2020.629722
Krajewski KM, Franchetti Y, Nishino M et al (2014) 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist 19(5):507–514. https://doi.org/10.1634/theoncologist.2013-0391
Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P (2013) Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol 2:22–29
Landi L, D’Incà F, Gelibter A et al (2019) Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer 7(1):316. https://doi.org/10.1186/s40425-019-0793-8
Lesterhuis WJ et al (2017) Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov 16:264–272
Li S, Zhang C, Pang G, Wang P (2020) Emerging blood-based biomarkers for predicting response to checkpoint immunotherapy in non-small-cell lung cancer. Front Immunol 11:603157. https://doi.org/10.3389/fimmu.2020.603157
Lopes GW, Kudaba I, Kowalski D, Cho BC, Castro G et al (2018) Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic nsclc with a PD-L1 tumor proportion score >=1%: open-label, phase 3 keynote-042 study. J Clin Oncol 36:36
Luo F, Zhang Z, Liao K et al (2019) Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. Ann Transl Med 7(12):253. https://doi.org/10.21037/atm.2019.04.65
Miyawaki T, Kenmotsu H, Mori K et al (2020) Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 21(5):e405–e414. https://doi.org/10.1016/j.cllc.2020.02.012
Nishino M, Ramaiya NH, Hatabu H, Hodi FS (2017) Monitoring immunecheckpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 14:655–668
Parvez K, Parvez A, Zadeh G (2014) The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci 15:11832–11846. https://doi.org/10.3390/ijms150711832
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265
Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (published correction appears in Lancet Oncol. 2019 May;20(5):e242). Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8
Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (published online ahead of print, 2021 Feb 4). CA Cancer J Clin. https://doi.org/10.3322/caac.21660
Thiam R, Fournier LS, Trinquart L et al (2010) Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 21(5):936–941. https://doi.org/10.1093/annonc/mdp466
Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287
Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624
Acknowledgements
We would like to sincerely appreciate all the patients and their family who were included in this retrospective study.
Funding
This work was not supported by external funders.
Author information
Authors and Affiliations
Contributions
SH: conceptualization, study design, methodology, project administration, supervision. WD, CC: resources, investigation, formal analysis. XZ, YZ, ZL: data curation, visualization. WD, CC: writing—original draft. SH, YZ and ZL: writing—reviewing and editing. All authors: final approval of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
All authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Du, W., Chen, C., Luo, Lf. et al. Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer. J Cancer Res Clin Oncol 149, 1103–1113 (2023). https://doi.org/10.1007/s00432-022-03978-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-03978-3